---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-267186"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2022-10-24T23:59:59+00:00"
generated_at: "2026-06-23T01:44:09.202815+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics launches RT-111 oral ustekinumab biosimilar; RT-102 data due Q4 2022; RT-109 halted

## Summary
- Preclinical development started for RT-111, an oral ustekinumab biosimilar for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
- RT-102 Phase 1 Part 2 (repeat-dose) topline data expected in Q4 2022; Phase 2 planned for H2 2023.
- In vivo studies with fully-autonomous RaniPill HC (high-capacity capsule) anticipated in Q4 2022.
- Active development of RT-109 (human growth hormone) discontinued; Rani open to partnering opportunities.
- Three additional Phase 1 studies targeted for 2023: RT-105 (adalimumab biosimilar), RT-110 (PTH for hypo-parathyroidism), and RT-111.

## SEC filing metadata
- accession: 0001193125-22-267186
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2022-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000119312522267186/0001193125-22-267186-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000119312522267186/d308091d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-267186
- JSON: https://secwatch.observer/filing/0001193125-22-267186.json
- Plain text: https://secwatch.observer/filing/0001193125-22-267186.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.